GTG Genetic Technologies Limited

Genetic Technologies Limited ("GTG") (Nasdaq:GENE) (ASX:GTG) is pleased to announce it has reached agreement with Bovigen LLC, of Louisiana, USA, on the terms of a license to be granted by GTG to Bovigen to GTG's non-coding patents. This license will enable Bovigen to build its business of offering genetic tests to the American livestock industry to determine the presence or absence of certain desirable traits in individual cattle. These tests are known to depend on analysis of non-coding DNA. The rights that GTG is now licensing to Bovigen are granted non-exclusively, and will be limited to applications in cattle in the USA, Canada and South America. The precise commercial terms are covered by confidentiality, but Bovigen will now pay to GTG an up-front signing fee plus ongoing royalties on the future sales by Bovigen, such that GTG will receive recurring revenues from this license for the life of the non-coding patents. About Genetic Technologies Limited Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (DeoxyriboNucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species. Its three-pronged business strategy includes: 1) the global commercialization of its patents through an active licensing program; 2) the expansion of its dominant commercial genetic testing business in Australia; and, 3) the commercialization of its various research and development projects aimed at generating further intellectual property of global commercial significance. About Bovigen, LLC Bovigen, LLC of Harahan, La., promotes excellence in the beef industry by developing, acquiring and commercializing genetic tools that enable producers to improve value and positively impact industry economics. The company's products include GeneSTAR(R) Tenderness; GeneSTAR(R) Quality Grade; SireTRACE(R); SureTRAK(R); and GeneSTAR(R) Black. This announcement may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as "should," "expects," "anticipates," "estimates," "believes" or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Genetic Technologies' current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.